Inventisbio Co.,Ltd.(688382),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

688382 Inventisbio Co.,Ltd.

Closed 04-03 15:00:00

22.80

-0.60

-2.56%

High23.40	Low22.50	Vol26.11M
Open23.33	D1 Closing23.40	Amplitude3.85%
Mkt Cap13.18B	Tradable Cap13.18B	Total Shares578.00M
T/O597.00M	T/O Rate4.52%	Tradable Shares578.00M
P/B7.92	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"688382","market":"SH","secType":"STK","nameCN":"Inventisbio Co.,Ltd.","latestPrice":22.8,"timestamp":1775199600000,"preClose":23.4,"halted":0,"volume":26106457,"delay":0,"changeRate":-0.0256,"floatShares":578000000,"shares":578000000,"eps":-0.2011,"marketStatus":"Closed","change":-0.6,"latestTime":"04-03 15:00:00","open":23.33,"high":23.4,"low":22.5,"amount":597000000,"amplitude":0.0385,"askPrice":22.8,"askSize":155,"bidPrice":22.79,"bidSize":132,"shortable":0,"etf":0,"ttmEps":-0.2011,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1775525400000},"marketStatusCode":5,"adr":0,"adjPreClose":23.4,"symbolType":"stock_kcb","openAndCloseTimeList":[[1775179800000,1775187000000],[1775192400000,1775199600000]],"highLimit":25.74,"lowLimit":21.06,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":578348491,"isCdr":false,"pbRate":7.92,"roa":"--","roe":"--","epsLYR":-0.4167,"committee":0.390947,"marketValue":13186000000,"turnoverRate":0.0451,"status":1,"nextConnectDate":"Northbound have stopped. The next trading day is UTC+8 2026-04-08.","afterMarket":{"amount":6840,"volume":300,"close":22.8,"buyVolume":376,"sellVolume":0,"time":1775201637919,"indexStatus":"Closed 04-03 15:30:00","preClose":23.4},"floatMarketCap":13186000000},"requestUrl":"/m/hq/s/688382/tweets","defaultTab":"tweets","newsList":[{"id":"2622984959","title":"InventisBio Completes Phase 3 Trial Patient Enrollment for Psoriasis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2622984959","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622984959?lang=en_us&edition=fundamental","pubTime":"2026-03-27 16:29","pubTimestamp":1774600174,"startTime":"0","endTime":"0","summary":"InventisBio  completed the enrollment of subjects for the phase 3 trial of its D-2570 drug for moderate-to-severe plaque psoriasis, according to a Friday filing with the Shanghai bourse.The drug could also be used to treat other autoimmune diseases, the filing said.D-2570 also received phase 2 drug trial approval for psoriasis in the U.S., the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168676750","title":"Inventisbio Cancels 2025 Restricted Stock Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1168676750","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168676750?lang=en_us&edition=fundamental","pubTime":"2026-03-27 15:42","pubTimestamp":1774597342,"startTime":"0","endTime":"0","summary":"Inventisbio Co.,Ltd. (688382.SH) announced that due to the impact of various factors, including the current macroeconomic environment, capital market conditions, and fluctuations in its secondary...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150325653","title":"Inventisbio Completes Patient Enrollment for Psoriasis Drug D-2570 Phase III Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1150325653","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150325653?lang=en_us&edition=fundamental","pubTime":"2026-03-26 16:57","pubTimestamp":1774515449,"startTime":"0","endTime":"0","summary":"Inventisbio Co.,Ltd. (688382.SH) announced that patient enrollment has been completed for the registrational Phase III clinical trial of its self-developed TYK2 inhibitor D-2570, intended for the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","BK0239","BK4134","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148039524","title":"Inventisbio Pursues Hong Kong IPO to Fund Pipeline Development Amid Persistent Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=1148039524","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148039524?lang=en_us&edition=fundamental","pubTime":"2026-03-19 16:42","pubTimestamp":1773909732,"startTime":"0","endTime":"0","summary":"As an innovative drug developer focused on oncology, metabolic, and autoimmune diseases, Inventisbio Co.,Ltd. has successfully launched two core products—befotertinib and glesoritib—which are now...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620419219","title":"InventisBio Reaches 30-Day Default Period for Clinical Trial Application for Psoriasis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2620419219","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620419219?lang=en_us&edition=fundamental","pubTime":"2026-03-19 14:26","pubTimestamp":1773901562,"startTime":"0","endTime":"0","summary":"InventisBio  reached the 30-day default period for a phase 2 clinical trial application to the U.S. Food and Drug Administration for its D-2570 monotherapy for psoriasis, according to a Thursday disclosure to the Shanghai bourse.The drug is indicated for other autoimmune conditions, the filing said.Shares fell nearly 2% during afternoon trading on Thursday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116273855","title":"Inventisbio's D-2570 Receives US FDA Clearance for Phase II Psoriasis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1116273855","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116273855?lang=en_us&edition=fundamental","pubTime":"2026-03-18 17:31","pubTimestamp":1773826299,"startTime":"0","endTime":"0","summary":"Inventisbio Co.,Ltd. has announced that its Investigational New Drug application for D-2570 as a monotherapy for psoriasis has passed the FDA's 30-day review period without objections. Consequently,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142647515","title":"Inventisbio's Financial Challenge: Why Two Marketed Drugs Fail to Halt Three-Year Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=1142647515","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142647515?lang=en_us&edition=fundamental","pubTime":"2026-03-12 17:16","pubTimestamp":1773307018,"startTime":"0","endTime":"0","summary":"Bringing an innovative drug from the laboratory to the market often requires a decade of effort and billions in funding. However, for Inventisbio Co.,Ltd., the greater challenge may lie in monetizing...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129010805","title":"Inventisbio (688382.SH) Forecasts Loss, Expects 2025 Net Loss of 292 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1129010805","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129010805?lang=en_us&edition=fundamental","pubTime":"2026-01-29 21:02","pubTimestamp":1769691774,"startTime":"0","endTime":"0","summary":"Inventisbio Co.,Ltd. (688382.SH) has issued an annual performance forecast for 2025, anticipating a net loss attributable to owners of the parent company of 292 million yuan for the year. The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191353278","title":"Inventisbio Pursues Hong Kong IPO: Befotinine Receivables Issue Remains Unresolved, Seeks Fresh Funding Despite Using 10 Billion Yuan Raised for Wealth Management","url":"https://stock-news.laohu8.com/highlight/detail?id=1191353278","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191353278?lang=en_us&edition=fundamental","pubTime":"2026-01-23 16:31","pubTimestamp":1769157088,"startTime":"0","endTime":"0","summary":"Against the backdrop of a surging wave of out-licensing for innovative drugs in China, Inventisbio Co.,Ltd., which has been listed on the STAR Market for three years, has formally submitted a main...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601798580","title":"InventisBio Submits Application for Hong Kong Share Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2601798580","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601798580?lang=en_us&edition=fundamental","pubTime":"2026-01-05 10:24","pubTimestamp":1767579861,"startTime":"0","endTime":"0","summary":"InventisBio  submitted documents for its planned share offering on the Hong Kong Stock Exchange, according to a Monday disclosure to the Shanghai bourse.The biopharmaceutical company intends to use the proceeds from its planned share offering for research and development of its core products and antibody-drug conjugates, and for working capital, according to an application proof submitted to the Hong Kong bourse Jan. 1.Shares rose 1% in Shanghai during morning trading on Monday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143371709","title":"New IPO News | Inventisbio (688382.SH) Submits Application to Hong Kong Stock Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=1143371709","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143371709?lang=en_us&edition=fundamental","pubTime":"2026-01-02 07:56","pubTimestamp":1767311776,"startTime":"0","endTime":"0","summary":"According to a disclosure by the Hong Kong Stock Exchange on January 1st, Inventisbio Co., Ltd. (Shanghai) has submitted a listing application for the Main Board of the Hong Kong Stock Exchange, with...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688382","BK0239","HEXmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187694823","title":"Inventisbio (688382.SH) Proposes 2025 Restricted Stock Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1187694823","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187694823?lang=en_us&edition=fundamental","pubTime":"2025-12-19 20:08","pubTimestamp":1766146109,"startTime":"0","endTime":"0","summary":"Inventisbio Co.,Ltd. (688382.SH) has disclosed a draft of its 2025 restricted stock incentive plan. The company plans to grant 5.577 million restricted shares to incentivized individuals,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590537333","title":"Biotech Firm InventisBio Explores Hong Kong IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2590537333","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590537333?lang=en_us&edition=fundamental","pubTime":"2025-12-10 08:29","pubTimestamp":1765326543,"startTime":"0","endTime":"0","summary":"InventisBio  plans to launch an initial public offering on the main board of the Hong Kong Stock Exchange, according to a Shanghai Stock Exchange filing on Wednesday.The Chinese biotech firm's board approved the plan on Monday.InventisBio said the move is aimed at enhancing its capital strength and better utilizing the diversified financing channels of the international capital market.The planned IPO is subject to approval from regulators in China and Hong Kong and the Hong Kong bourse operator.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187926654","title":"Inventisbio Co.,Ltd. Plans to Issue H Shares and List on Hong Kong Stock Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=1187926654","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187926654?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:11","pubTimestamp":1765282281,"startTime":"0","endTime":"0","summary":"On December 9, Inventisbio Co.,Ltd. (688382.SH) announced its intention to issue H shares overseas and apply for a listing on the main board of the Hong Kong Stock Exchange.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590310066","title":"Inventisbio  Says Co Plans to Seek Hong Kong Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2590310066","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590310066?lang=en_us&edition=fundamental","pubTime":"2025-12-09 19:17","pubTimestamp":1765279037,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nL4N3XF0TP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590096310","title":"BRIEF-InventisBio Plans To Seek Hong Kong Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2590096310","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590096310?lang=en_us&edition=fundamental","pubTime":"2025-12-09 19:17","pubTimestamp":1765279037,"startTime":"0","endTime":"0","summary":"BRIEF-InventisBio Plans To Seek Hong Kong ListingDec 9 (Reuters) - InventisBio Co Ltd 688382.SS:SAYS CO PLANS TO SEEK HONG KONG LISTINGSource textFurther company coverage: 688382.SS (Reporting by Beijing Newsroom) ((Shi.Bu@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nL4N3XF0TP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-07-25","address":"上海市浦东新区中国(上海)自由贸易试验区李冰路67弄4号210室","stockEarnings":[{"period":"1week","weight":0.3065},{"period":"1month","weight":0.1741},{"period":"3month","weight":-0.141},{"period":"6month","weight":-0.2478},{"period":"1year","weight":0.1398},{"period":"ytd","weight":-0.141}],"companyName":"益方生物科技(上海)股份有限公司","boardCode":"AI0027","perCapita":"46822股","boardName":"医药制造业","registeredCapital":"57834万元","compareEarnings":[{"period":"1week","weight":0.0078},{"period":"1month","weight":-0.0493},{"period":"3month","weight":-0.0125},{"period":"6month","weight":0.0094},{"period":"1year","weight":0.1699},{"period":"ytd","weight":-0.0125}],"survey":"　　益方生物科技(上海)股份有限公司的主营业务是创新药物的研发、生产和销售。公司的主要产品是对外授权产品贝福替尼、对外授权产品格索雷塞、临床试验阶段产品Taragarestrant、临床试验阶段产品D-0120、临床试验阶段产品D-2570。","serverTime":1775201736038,"listedPrice":18.12,"stockholders":"12352人(较上一季度增加26.17%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Inventisbio Co.,Ltd.(688382),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Inventisbio Co.,Ltd.(688382) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Inventisbio Co.,Ltd.,688382,Inventisbio Co.,Ltd.股票,Inventisbio Co.,Ltd.股票老虎,Inventisbio Co.,Ltd.股票老虎国际,Inventisbio Co.,Ltd.行情,Inventisbio Co.,Ltd.股票行情,Inventisbio Co.,Ltd.股价,Inventisbio Co.,Ltd.股市,Inventisbio Co.,Ltd.股票价格,Inventisbio Co.,Ltd.股票交易,Inventisbio Co.,Ltd.股票购买,Inventisbio Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Inventisbio Co.,Ltd.(688382),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Inventisbio Co.,Ltd.(688382) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction